Conditions

A new weight loss device, AspireAssist, offers a novel approach to cutting calories: draining them from the stomach before they are fully digested. The AspireAssist® system consists of a thin tube implanted in the stomach, connecting to an outside port on the skin of the belly.

In this week's Homerun Slides, prioritizing patient characteristics to determine best type 2 treatment agent.

Part 2 of our ADA Rundown checks out the latest information on competing long-acting insulins, and the ongoing research into potential class effect benefits for cardiovascular outcomes: as data shows CV benefits for DPP-4 and SGLT-2 treatments, are GLP-1 treatments under pressure?

In part 1 of our ADA Rundown, we look at cardiovascular benefits for multiple drugs, new combination treatments, and the possibility that Invokana's weight loss benefits may also apply to people who don't have diabetes.

In this week's Homerun Slides, the Canadian Diabetes Association's guidelines for the pharmacologic treatment of type 2 diabetes, which dictate that the choice of therapy depends on glycemia.

Elevated 1-hour level proves significant despite 2-hour level within normal glucose tolerance range.

Study suggests wine consumption offers greater protection against type 2 risk, compared with beer or other alcoholic beverages.

In this week's Homerun Slides, the cost of the current diabetes classification.

New guidelines cite effectiveness, cost efficiency, and safety as reasons to consider procedure.

Higher level of cardiorespiratory fitness (CRF) over two decades was shown to reduce risk for developing prediabetes and T2, even after adjusting for changes in BMI.